Eosinophil Accumulation in Pulmonary Airways of Guinea-pigs Induced by Exposure to an Aerosol of Platelet-activating Factor: Effect of Anti-asthma Drugs

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1990 Feb 1

PMID 2328394

Citations 18

Authors

S Sanjar

S Aoki

K Boubekeur

I D Chapman

D Smith

M A Kings

J Morley

Affiliations

Soon will be listed here.

Abstract

1. Exposure of guinea-pigs to aerosols of platelet activating factor (PAF) (0.01 to 100 micrograms ml-1) induced a dose-dependent increased incidence of eosinophils in bronchoalveolar lavage fluid (BAL) at 48 h. Total leucocyte numbers and the percentages of lymphocytes and neutrophils were unchanged in BAL fluid. 2. Increased numbers of eosinophils were detected in BAL 1 h after exposure to PAF but eosinophilia was not maximal until 48 h. One week after exposure to PAF, the percentage of eosinophils in BAL was within the normal range. 3. Depletion of circulating platelets or neutrophils by intravenous injection of specific antisera did not modify accumulation of eosinophils in the airway lumen following inhalation of PAF (10 micrograms ml-1). 4. PAF-induced pulmonary airway eosinophil accumulation was inhibited by treatment with SDZ 64-412, a selective PAF-antagonist, whether the compound was administered before, or 30 min after, inhalation of PAF. 5. Pulmonary airway eosinophil accumulation due to inhaled PAF (10 micrograms ml-1) was inhibited by prior treatment with aminophylline, cromoglycate, ketotifen, dexamethasone and AH 21-132. 6. Pulmonary airway eosinophil accumulation due to inhaled PAF (10 micrograms ml-1) was not inhibited by prior treatment with indomethacin, salbutamol or mepyramine.

Citing Articles

Protein tyrosine phosphatase 11 acts through RhoA/ROCK to regulate eosinophil accumulation in the allergic airway.

Xu C, Wu X, Lu M, Tang L, Yao H, Wang J FASEB J. 2019; 33(11):11706-11720.

PMID: 31361966 PMC: 6902720. DOI: 10.1096/fj.201900698R.

Ozone differentially modulates airway responsiveness in atopic versus nonatopic guinea pigs.

Schlesinger R, Cohen M, Gordon T, Nadziejko C, Zelikoff J, Sisco M Inhal Toxicol. 2002; 14(5):431-57.

PMID: 12028802 PMC: 2978653. DOI: 10.1080/089583701753678562.

The diverse effects of mast cell mediators.

Hines C Clin Rev Allergy Immunol. 2002; 22(2):149-60.

PMID: 11975420 DOI: 10.1385/CRIAI:22:2:149.

Early bronchial hyperresponsiveness following injection of sephadex beads in the guinea pig: involvement of platelet activating factor and thromboxane A2.

Conroy D, Sirois P Inflammation. 1999; 23(5):437-48.

PMID: 10466580 DOI: 10.1023/a:1021913009742.

The effect of platelet-activating factor on the responsiveness of the human nasal airway.

Austin C, Foreman J Br J Pharmacol. 1993; 110(1):113-8.

PMID: 8220870 PMC: 2176011. DOI: 10.1111/j.1476-5381.1993.tb13779.x.

References

Horn B, Robin E, Theodore J, Van Kessel A . Total eosinophil counts in the management of bronchial asthma. N Engl J Med. 1975; 292(22):1152-5. DOI: 10.1056/NEJM197505292922204. View

Benveniste J, Henson P, Cochrane C . Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med. 1972; 136(6):1356-77. PMC: 2139324. DOI: 10.1084/jem.136.6.1356. View

Brown H, STOREY G, JACKSON F . Beclomethasone dipropionate aerosol in long-term treatment of perennial and seasonal asthma in children and adults: a report of five-and-half years' experience in 600 asthmatic patients. Br J Clin Pharmacol. 1977; 4 Suppl 3:259S-267S. PMC: 1428855. DOI: 10.1111/j.1365-2125.1977.tb04517.x. View

Gobel P . The protective effect of ketotifen in bronchial asthma. J Int Med Res. 1978; 6(2):78-85. View

Dahl R, Venge P, Olsson I . Variations of blood eosinophils and eosinophil cationic protein in serum in patients with bronchial asthma. Studies during inhalation challenge test. Allergy. 1978; 33(4):211-5. DOI: 10.1111/j.1398-9995.1978.tb01536.x. View

Vargaftig B, Lefort J, Chignard M, Benveniste J . Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol. 1980; 65(2-3):185-92. DOI: 10.1016/0014-2999(80)90391-x. View

Frigas E, Loegering D, Solley G, Farrow G, Gleich G . Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc. 1981; 56(6):345-53. View

Arnoux B, Duval D, Benveniste J . Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest. 1980; 10(6):437-41. DOI: 10.1111/j.1365-2362.1980.tb02082.x. View

Dahl R, Venge P . Role of the eosinophil in bronchial asthma. Eur J Respir Dis Suppl. 1982; 122:23-8. View

10.

Camussi G, Pawlowski I, Tetta C, Roffinello C, Alberton M, Brentjens J . Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. Am J Pathol. 1983; 112(1):78-88. PMC: 1916326. View

11.

Verhagen J, Bruynzeel P, Koedam J, Wassink G, de Boer M, Terpstra G . Specific leukotriene formation by purified human eosinophils and neutrophils. FEBS Lett. 1984; 168(1):23-8. DOI: 10.1016/0014-5793(84)80199-4. View

12.

Lee T, Lenihan D, Malone B, Roddy L, Wasserman S . Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984; 259(9):5526-30. View

13.

Diaz P, Galleguillos F, Gonzalez M, Pantin C, Kay A . Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. J Allergy Clin Immunol. 1984; 74(1):41-8. DOI: 10.1016/0091-6749(84)90085-x. View

14.

Lefort J, Rotilio D, Vargaftig B . The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. Br J Pharmacol. 1984; 82(3):565-75. PMC: 1987001. DOI: 10.1111/j.1476-5381.1984.tb10795.x. View

15.

Dewar A, Archer C, Paul W, Page C, Macdonald D, Morley J . Cutaneous and pulmonary histopathological responses to platelet activating factor (Paf-acether) in the guinea-pig. J Pathol. 1984; 144(1):25-34. DOI: 10.1002/path.1711440104. View

16.

de Monchy J, Kauffman H, Venge P, Koeter G, Jansen H, SLUITER H . Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985; 131(3):373-6. DOI: 10.1164/arrd.1985.131.3.373. View

17.

Archer C, Page C, Morley J, Macdonald D . Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man. Br J Dermatol. 1985; 112(3):285-90. DOI: 10.1111/j.1365-2133.1985.tb04855.x. View

18.

Godeneche D, Chabard J, Petit J, Berger J . Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. Agents Actions. 1984; 15(5-6):643-8. DOI: 10.1007/BF01966786. View

19.

Frigas E, Gleich G . The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 1986; 77(4):527-37. DOI: 10.1016/0091-6749(86)90341-6. View

20.

SPICER B, Laycock S, Smith H . The effects of drugs on leucocyte changes following the injection of antigen into the peritoneal cavities of actively sensitised rats. Agents Actions. 1986; 17(5-6):498-505. DOI: 10.1007/BF01965521. View